Rectal bacteriotherapy for recurrent Clostridium difficile-associated diarrhoea: Results from a case series of 55 patients in Denmark 2000-2012

Clinical Microbiology and Infection

Volumn 21, Issue 1, 2015, Pages 48-53

  Tvede, M ^a   Tinggaard, M ^b   Helms, M ^c  

^a Rigshospitalet   (Denmark)

^b HOLBÆK HOSPITAL   (Denmark)

^c Mental Health Services CPH   (Denmark)

Author keywords

Case series; Faecal bacteriotherapy; Recurrent Clostridium difficile

Indexed keywords

AMPICILLIN; CEPHALOSPORIN DERIVATIVE; GENTAMICIN; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; VANCOMYCIN;

ADULT; AGED; APPENDICITIS; ARTICLE; BACTEREMIA; BACTERIUM CULTURE; BACTEROIDES OVATUS; BACTEROIDES THETAIOTAOMICRON; BACTEROIDES VULGATUS; CLINICAL EFFECTIVENESS; CLOSTRIDIUM BIFERMENTANS; CLOSTRIDIUM DIFFICILE INFECTION; CLOSTRIDIUM INNOCUUM; CONTROLLED STUDY; ENTEROCOCCUS FAECALIS; ERYSIPELATOCLOSTRIDIUM RAMOSUM; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; EXPERIMENTAL THERAPY; FECES MICROFLORA; FEMALE; FEVER; HUMAN; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS RHAMNOSUS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; NONHUMAN; PRIORITY JOURNAL; RECTAL BACTERIOTHERAPY; RECURRENT DISEASE; VERY ELDERLY; YOUNG ADULT; BACTERIUM; BIOLOGICAL THERAPY; CLOSTRIDIUM INFECTIONS; DENMARK; FECES; HOSPITALIZATION; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

BACTERIA (MICROORGANISMS); CLOSTRIDIUM DIFFICILE; ESCHERICHIA COLI;

ADULT; AGED; AGED, 80 AND OVER; BACTERIA; BIOLOGICAL THERAPY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DENMARK; FECES; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84926298450     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2014.07.003     Document Type: Article

References (30)

1. Larson H.E., Price A.B., Honour P., Borriello S.P. Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet 1978, 1:1063-1066.
2. Wiegand P.N., Nathwani D., Wilcox M.H., Stephens J., Shelbaya A., Haider S. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. JHosp Infect 2012, 81:1-14.
3. Bakken J.S., Borody T., Brandt L.J., Brill J.V., Demarco D.C., Franzos M.A., et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011, 9:1044-1049.
4. O'Donoghue C., Kyne L. Update on Clostridium difficile infection. Curr Opin Gastroenterol 2011, 27:38-47.
5. Bacci S., Molbak K., Kjeldsen M.K., Olsen K.E. Binary toxin and death after Clostridium difficile infection. Emerg Infect Dis 2011, 17:976-982.
6. Lo V.A., Zacur G.M. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol 2012, 28:1-9.
7. Bauer M.P., Kuijper E.J., van Dissel J.T. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009, 15:1067-1079.
8. Bartlett J.G. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006, 145:758-764.
9. Musher D.M., Aslam S., Logan N., Nallacheru S., Bhaila I., Borchert F., et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005, 40:1586-1590.
10. Louie T.J., Miller M.A., Mullane K.M., Weiss K., Lentnek A., Golan Y., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. NEngl J Med 2011, 364:422-431.
11. van Nispen tot Pannerden C.M., Verbon A., Kuipers E.J. Recurrent Clostridium difficile infection: what are the treatment options?. Drugs 2011, 71:853-868.
12. Fekety R., McFarland L.V., Surawicz C.M., Greenberg R.N., Elmer G.W., Mulligan M.E. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997, 24:324-333.
13. Garey K.W., Sethi S., Yadav Y., Dupont H.L. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. JHosp Infect 2008, 70:298-304.
14. Johnston B.C., Ma S.S., Goldenberg J.Z., Thorlund K., Vandvik P.O., Loeb M., et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med 2012, 157:878-888.
15. Gerding D.N., Johnson S. Management of Clostridium difficile infection: thinking inside and outside the box. Clin Infect Dis 2010, 51:1306-1313.
16. Tvede M., Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1989, 1:1156-1160.
17. Petrof E.O., Gloor G.B., Vanner S.J., Weese S.J., Carter D., Daigneault M.C., et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome 2013, 1:3.
18. Lawley T.D., Clare S., Walker A.W., Stares M.D., Connor T.R., Raisen C., et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog 2012, 8:e1002995.
19. Guo B., Harstall C., Louie T., Veldhuyzen van Z.S., Dieleman L.A. Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease. Aliment Pharmacol Ther 2012, 35:865-875.
20. Eiseman B., Silen W., Bascom G.S., Kauvara A.J. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958, 44:854-859.
21. Schwan A., Sjolin S., Trottestam U., Aronsson B. Relapsing clostridium difficile enterocolitis cured by rectal infusion of homologous faeces. Lancet 1983, 2:845.
22. Aas J., Gessert C.E., Bakken J.S. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003, 36:580-585.
23. Yoon S.S., Brandt L.J. Treatment of refractory/recurrent C.difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients. JClin Gastroenterol 2010, 44:562-566.
24. Jorup-Rönstroöm C., Håkanson A., Sandell S., Edvinsson O., Midtvedt T., Persson A.K., et al. Fecal transplant against relapsing Clostridium difficile-associated diarrhea in 32 patients. Scand J Gastroenterol 2012, 47:548-552.
25. Hamilton M.J., Weingarden A.R., Sadowsky M.J., Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 2012, 107:761-777.
26. van Nood E., Dijkgraaf M.G., Keller J.J. Duodenal infusion of feces for recurrent Clostridium difficile. NEngl J Med 2013, 368:2145.
27. Jacobsen C.N., Rosenfeldt Nielsen V., Hayford A.E., Møller P.L., Michaelsen K.F., Paerregaard A., et al. Screening of probiotic activities of forty-seven strains of Lactobacillus spp. by invitro techniques and evaluation of the colonization ability of five selected strains in humans. Appl Environ Microbiol 1999, 65:4949-4956.
28. Tedesco F., Markham R., Gurwith M., Christie D., Bartlett J.G. Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet 1978, 2:226-228.
29. Charlson M.E., Pompei P., Ales K.L., Mackenzie C.R. Anew method of classifying prognostic comorbidity in longitudinal studies: development and validation. JChronic Dis 1987, 40:373-383.
30. Mole B. FDA gets to grips with faeces. Nature 2013, 498:147-148.